C12N 2710/16671
Demonstrated in vivo effect
C12N2710/16671 (Demonstrated in vivo effect) appears on 57 US grants and 99 published applications in this corpus.
Search patents in C12N- Granted patents
- 57
- Published applications
- 99
- Assignees
- 57
- Inventors
- 161
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 2 | 3 |
| 2014 | 1 | 1 |
| 2015 | 2 | 7 |
| 2016 | 1 | 6 |
| 2017 | 3 | 9 |
| 2018 | 6 | 5 |
| 2019 | 8 | 9 |
| 2020 | 7 | 11 |
| 2021 | 4 | 8 |
| 2022 | 6 | 5 |
| 2023 | 5 | 13 |
| 2024 | 3 | 7 |
| 2025 | 4 | 7 |
| 2026 | 4 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof26 May 2026US 12,636,329 B2
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Compositions and methods for delivering CFTR polypeptides13 Jan 2026US 12,522,636 B2Krystal Biotech, Inc.
- Generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use30 Dec 2025US 12,509,662 B2The Brigham and Women's Hospital, Inc.
- Use of oncolytic viruses for the treatment of cancer24 Sep 2026US 2026/0286393 A1Amgen Inc.
- Viral Vectors for Cancer Therapy30 Apr 2026US 2026/0115327 A1Krystal Biotech, Inc.
- Compositions and Methods for Delivering CFTR Polypeptides30 Apr 2026US 2026/0116934 A1Krystal Biotech, Inc.
- Macrophage polarizing oncolytic herpes simplex virus for cancer therapy9 Apr 2026US 2026/0097088 A1Research Institute At Nationwide Children's Hospital
- Recombinant herpes simplex virus-2 expressing glycoprotein d and b antigens4 Dec 2025US 2025/0367279 A1The Brigham and Women S Hospital, Inc.
Most cited
By later US patents
- Viral vectors and their use in therapeutic methods31US 7,749,745 B2Georgetown University · 2010
- Viral vectors and their use in therapeutic methods20US 8,470,577 B2Catherex, Inc. · 2013
- Viral vectors and their use in therapeutic methods16US 8,871,193 B2Catherex, Inc. · 2014
- Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors16US 9,593,347 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2017
- Mutant herpes simplex virus-2 for cancer therapy15US 10,039,796 B2University of Houston System · 2018